

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Renu Wadhwa et al.                      Art Unit : 1644  
Serial No. : 09/684,579                              Examiner : A. DeCloux  
Filed : October 6, 2000  
Title : PROTEIN AND GENE INVOLVED IN MYOCYTE DIFFERENTIATION

**BOX SEQUENCE**

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated December 13, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit a substitute Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

Replace the original Sequence Listing with the substitute Sequence Listing filed herewith.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

January 14, 2002

Date of Deposit

Signature

Jennifer H. Payne

Typed or Printed Name of Person Signing Certificate

Replace the paragraph beginning at page 18, line 1, with the following rewritten paragraph:

--A plasmid expressing the reporter in response to p53 has the reporter gene located downstream of a p53 responsive sequence. "ATGCTTGCCC" (SEQ ID NO:17) may be used as the p53 responsive sequence. There are no particular restrictions as to the reporter gene used as long as it has a detectable response. Genes such as those for luciferase and  $\beta$ -galactosidase can be used.--

Replace the paragraph beginning at page 20, line 22, with the following rewritten paragraph:

--Figure 1 shows the nucleotide sequence of striamin and its predicted amino acid sequence (SEQ ID NOs:2 and 1, respectively). The sequence of in-frame codons and the 5' upstream sequence obtained by 5' RACE PCR on the mouse skeletal muscle cDNA are underlined.--

Applicant : Renu Wadhwa et al.  
Serial No. : 09/684,579  
Filed : October 6, 2000  
Page : 3

Attorney's Docket No.: 06501-066001 / C2-903PCT-  
US

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert sequence identifiers in the specification and replace the original Sequence Listing with an amended substitute Sequence Listing. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 06501-066001.

Respectfully submitted,

Date: January 14, 2002

Diane Collins Reg. No. 46,635  
for Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

**“Version With Markings to Show Changes Made”**

In the specification:

Paragraph beginning at page 18, line 1, has been amended as follows:

A plasmid expressing the reporter in response to p53 has the reporter gene located downstream of a p53 responsive sequence. “ATGCTTGCCC” (SEQ ID NO:17) may be used as the p53 responsive sequence. There are no particular restrictions as to the reporter gene used as long as it has a detectable response. Genes such as those for luciferase and  $\beta$ -galactosidase can be used.

Paragraph beginning at page 20, line 22, has been amended as follows:

Figure 1 shows the nucleotide sequence of striamin and its predicted amino acid sequence (SEQ ID NOs:2 and 1, respectively). The sequence of in-frame codons and the 5' upstream sequence obtained by 5' RACE PCR on the mouse skeletal muscle cDNA are underlined.

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: See attached communication.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**